Myogem Health Company S.L. is a company located in Mollet del Valles, Barcelona, ​​Spain.

The company is a spin-off of Inkemia IUCT Group, oriented to research, development, innovation and marketing of new nutritional products aimed at improving the quality of life of people affected by certain rare or infrequent diseases and / or high social impact . A rare disease is one that affects a small absolute number of people or a small proportion of the population. In Europe, a disease that affects less than 1 in 2 000 people is considered "rare". In the United States, this is defined as a disorder or illness suffered by less than 200,000 people.

Our mission

The Myogem Health Company's mission is to offer patients affected by these diseases the possibility of having a better quality of life through a range of food products aimed at improving their nutritional status. Currently, Myogem Health Company focuses its research on the search for new nutritional solutions aimed at diseases of neuromuscular origin, such as myotonic dystrophy type 1 or Steinert's disease.

Our objetive

Traditionally, medications have been considered as the only option to improve the quality of life. However, many factors influence the quality of life, which can be modulated through improving vitality, the perception of general health, the physical, emotional and social condition, and mental health of an individual. A current approach to improve the quality of life consists in the nutritional management of the pathological condition that is limiting it. Myogem Health Company aims to be a benchmark company in research and development of nutritional products based on food ingredients that provide an improvement in the quality of life and nutritional status of people affected by certain rare diseases, such as myotonic dystrophy type 1 , and other related diseases.

 

MANAGEMENT TEAM.

Héctor Gil.  - Administration Counsel President

Javier Fuentes.  - Regulatory affairs and Head of QA and QC

Paqui Miranda.  - Director of Galenic Development

Marta Pascual Gilabert.  - Scientific Director

Mr. Álex Duran.  - Director of Product Development